How big is the EGFR Market | Size, Growth, and Applications 2025

Q: What is the EGFR market size?

The EGFR market was projected at approximately USD 5.9 billion by 2031.

Q: What is the projected growth rate of the EGFR market?

The EGFR market is projected to grow at a CAGR of 12.3% from 2025 to 2031.

Q: What are the major applications of EGFR-targeted therapies?

Major applications include treatment of non-small cell lung cancer, colorectal cancer, glioblastoma, and pancreatic cancer.

Q: What are the key challenges in the EGFR market?

Challenges include drug resistance mutations, high therapy costs, and limited awareness in low-income regions.

Q: Which regions are showing the fastest growth in EGFR therapy adoption?

Asia-Pacific and Latin America are expected to grow rapidly due to rising cancer incidence and improved diagnostics.

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA5875

Publication Date: Jul 2025

How big is the EGFR market?

According to 6Wresearch internal database and industry insights, the Epidermal Growth Factor Receptor (EGFR) market was valued at approximately USD 2.6 billion in 2024 and is projected to reach USD 5.9 billion by 2031, growing at a CAGR of 12.3% during the forecast period.

This growth is driven by the rising incidence of non-small cell lung cancer (NSCLC) and colorectal cancers, expanding clinical use of EGFR inhibitors, and increasing availability of targeted biologics and biosimilars. Technological advancements in precision oncology, companion diagnostics, and the emergence of next-generation EGFR inhibitors are further accelerating market expansion.

Key Growth Factors of the EGFR Market

Rising prevalence of EGFR mutation-positive cancers, particularly NSCLC
Increased adoption of personalized cancer therapies and precision medicine
Development of third-generation EGFR-TKIs with improved resistance profiles
Expanding access to molecular diagnostics and biomarker screening
Favorable regulatory approvals and oncology R&D investments
Growing demand for targeted therapies in emerging healthcare markets

EGFR Market Trends

The EGFR market is witnessing a shift toward mutation-specific therapies and combination regimens targeting resistance mechanisms. The integration of companion diagnostics is becoming standard in oncology treatment pathways. While North America dominates due to advanced healthcare infrastructure and drug accessibility, Asia-Pacific is seeing fast-paced growth driven by rising cancer rates and improved screening programs. The market is also seeing increased penetration of biosimilar EGFR inhibitors in cost-sensitive regions.

Emerging Developments in the EGFR Market

Research efforts are increasingly focused on next-generation EGFR inhibitors that address T790M and C797S mutations. Liquid biopsy-based EGFR detection is gaining traction for its non-invasive benefits. Pharma companies are exploring EGFR-targeting antibody-drug conjugates (ADCs) and dual-target therapies. Regulatory agencies are also streamlining approvals for mutation-specific indications, enhancing market dynamics.